AR114350A1 - Terapia genética para la distrofia muscular de cinturas del tipo 2c - Google Patents

Terapia genética para la distrofia muscular de cinturas del tipo 2c

Info

Publication number
AR114350A1
AR114350A1 ARP190100213A ARP190100213A AR114350A1 AR 114350 A1 AR114350 A1 AR 114350A1 AR P190100213 A ARP190100213 A AR P190100213A AR P190100213 A ARP190100213 A AR P190100213A AR 114350 A1 AR114350 A1 AR 114350A1
Authority
AR
Argentina
Prior art keywords
type
dystrophy
muscular
waist
genetic therapy
Prior art date
Application number
ARP190100213A
Other languages
English (en)
Inventor
Louise R Rodino-Klapac
Original Assignee
Res Institute At Nationwide Children’S Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Institute At Nationwide Children’S Hospital filed Critical Res Institute At Nationwide Children’S Hospital
Publication of AR114350A1 publication Critical patent/AR114350A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707Muscular dystrophy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vectores de terapia genética tales como vectores AAV. que comprenden un polinucleótido que codifica sarcoglicano (SGCG) y métodos para usar tales vectores de terapia genética para el tratamiento de sujetos que sufren de distrofia muscular, por ejemplo distrofia muscular de cinturas del tipo 2C (LGMD2C).
ARP190100213A 2018-01-31 2019-01-30 Terapia genética para la distrofia muscular de cinturas del tipo 2c AR114350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862624616P 2018-01-31 2018-01-31

Publications (1)

Publication Number Publication Date
AR114350A1 true AR114350A1 (es) 2020-08-26

Family

ID=67478478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100213A AR114350A1 (es) 2018-01-31 2019-01-30 Terapia genética para la distrofia muscular de cinturas del tipo 2c

Country Status (17)

Country Link
US (1) US20200360534A1 (es)
EP (1) EP3746100A4 (es)
JP (2) JP7361701B2 (es)
KR (1) KR20200115585A (es)
CN (1) CN111818946A (es)
AR (1) AR114350A1 (es)
AU (1) AU2019216257A1 (es)
BR (1) BR112020015173A2 (es)
CA (1) CA3089080A1 (es)
CL (2) CL2020001948A1 (es)
CO (1) CO2020010270A2 (es)
EA (1) EA202091739A1 (es)
IL (1) IL275880A (es)
MX (1) MX2020007876A (es)
SG (1) SG11202006722RA (es)
TW (1) TWI815856B (es)
WO (1) WO2019152474A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200115598A (ko) 2018-01-30 2020-10-07 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
EP4051324A4 (en) * 2019-10-28 2023-11-29 University Of Florida Research Foundation, Incorporated GENE THERAPY VECTORS
EP4117783A4 (en) * 2019-12-16 2024-08-21 Res Inst Nationwide Childrens Hospital COMPOSITIONS AND METHODS FOR RESTORING AND MAINTAINING DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX (DAPC)
CN116348149A (zh) * 2020-06-15 2023-06-27 全国儿童医院研究所 用于肌营养不良症的腺相关病毒载体递送
EP4168052A2 (en) 2020-06-19 2023-04-26 Genethon Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
TW202227634A (zh) 2020-09-08 2022-07-16 美商薩羅塔治療公司 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
JP2023081369A (ja) * 2021-11-30 2023-06-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
EP4198134A1 (en) 2021-12-16 2023-06-21 Genethon Gamma-sarcoglycan gene transfer increase using modified itr sequences

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262035B1 (en) * 1998-10-01 2001-07-17 University Of Iowa Research Foundation Gene replacement therapy for muscular dystrophy
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
DE18200782T1 (de) * 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) * 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3452101A2 (en) * 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
WO2019152474A1 (en) 2019-08-08
US20200360534A1 (en) 2020-11-19
SG11202006722RA (en) 2020-08-28
CL2021003097A1 (es) 2022-07-15
JP2023171900A (ja) 2023-12-05
EP3746100A4 (en) 2021-11-17
JP2021512072A (ja) 2021-05-13
KR20200115585A (ko) 2020-10-07
CL2020001948A1 (es) 2020-10-09
JP7361701B2 (ja) 2023-10-16
TWI815856B (zh) 2023-09-21
CA3089080A1 (en) 2019-08-08
CN111818946A (zh) 2020-10-23
TW201934751A (zh) 2019-09-01
BR112020015173A2 (pt) 2020-12-29
WO2019152474A9 (en) 2020-08-27
MX2020007876A (es) 2020-12-03
EP3746100A1 (en) 2020-12-09
IL275880A (en) 2020-08-31
EA202091739A1 (ru) 2021-01-14
AU2019216257A1 (en) 2020-07-23
CO2020010270A2 (es) 2020-11-20

Similar Documents

Publication Publication Date Title
AR114350A1 (es) Terapia genética para la distrofia muscular de cinturas del tipo 2c
CO2018012084A2 (es) Administración de vectores del virus adenoasociado de microdistrofina para tratar la distrofia muscular
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
CO2019011250A2 (es) Administración de vectores del virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
CL2020003289A1 (es) Suministro en vector del virus adeno-asociado de micro-distrofina específica de músculos para tratar la distrofia muscular
MX2016001204A (es) Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo.
MX2020005470A (es) Composiciones y metodos para enfermedades neurologicas.
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
CO2021012074A2 (es) Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular
ZA201803080B (en) Methods of treating muscular dystrophy
MX2021005435A (es) Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2).
NZ765719A (en) Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
MX2021014337A (es) Vectores de genoterapia para osteopetrosis maligna infantil.
MX2015007650A (es) Tratamiento de retinitis pigmentosa.
MX2019010599A (es) Usos medicos para tratamiento de retinitis pigmentosa.
MA42736B1 (fr) Méthodes de traitement de la dystrophie musculaire
EA201892338A1 (ru) Доставка микродистрофина вектором на основе аденоассоциированного вируса для лечения мышечной дистрофии